Piper Sandler upgraded Organon (OGN) to Neutral from Underweight with a price target of $14, up from $5, after the company entered into an agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14 per share in an all-cash transaction. Piper views the deal as “lightning in a bottle” for Organon. The firm is surprised a buyer emerge d given its views on Organon’s asset quality.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: